Aficamten Improves Symptoms and Exercise Capacity in Non-Obstructive HCM

Aficamten, a novel myosin‑inhibitor therapy, has shown marked benefits for patients with symptomatic non‑obstructive hypertrophic cardiomyopathy (HCM), according to data presented at the European Society of Cardiology (ESC) Congress 2026 and published concurrently in the *New England Journal of Medicine*. In a Hot Line session, investigators highlighted that the drug significantly reduced patients’ symptom burden and improved exercise capacity compared with standard care.

The study enrolled adults with non‑obstructive HCM who reported symptoms such as dyspnea, chest pain, or fatigue. Over a 12‑month period, those receiving aficamten experienced a statistically significant decrease in the Kansas City Cardiomyopathy Questionnaire score and an increase in peak oxygen uptake during cardiopulmonary exercise testing. The safety profile was consistent with previous trials, with most adverse events being mild and reversible. These findings suggest that aficamten may address a therapeutic gap for HCM patients who do not exhibit left‑ventricular outflow‑tract obstruction.

If confirmed in larger, long‑term trials, aficamten could become a first‑line option for symptomatic non‑obstructive HCM, offering a targeted approach that improves functional status without the need for invasive procedures. The ESC and NEJM publications underscore the potential of myosin‑modulating agents to transform care for this growing patient population.